Effects of linagliptin on inflammatory factors and arteriosclerosis in patients with newly diagnosed type 2 diabetes mellitus  

利格列汀对初诊2型糖尿病患者炎症因子和动脉硬化的影响

作　　者：Rui Li Yanru Kong 李睿;孔燕茹(山东大学第二医院急诊科,山东济南250033;山东大学第二医院超声科,山东济南250033)

机构地区：[1]Department of Emergency,The Second Hospital,Cheeloo College of Medicine,Shandong University,Jinan 250033,Shandong,China [2]Department of Echocardiography,The Second Hospital,Cheeloo College of Medicine,Shandong University,Jinan 250033,Shandong,China

出　　处：《Journal of Chinese Pharmaceutical Sciences》2021年第8期692-698,共7页中国药学（英文版）

摘　　要：In the present study,we aimed to investigate the effects of linagliptin on inflammatory factors and carotid intima-media thickness(CIMT)in newly diagnosed type 2 diabetes mellitus(T2 DM)patients with carotid atherosclerotic disease(CAD).A total of 326 patients with newly diagnosed T2 DM complicated with CAD were randomly divided into two groups.There were 163 patients in the control group,who were treated with metformin monotherapy.There were 163 patients in the experimental group,who were treated with metformin in combination with linagliptin.The CIMT before and after treatment was measured by color Doppler ultrasound,and the contents of IL-6 and IL-1βbefore and after treatment were detected by ELISA.The levels of inflammatory factors and CIMT before and after treatment were compared between the two groups,and the correlation between IL-6,IL-1βand CIMT was studied.After 24 weeks of treatment,the levels of inflammatory factors and CIMT in the experimental group were significantly lower compared with the control group(P<0.01),and the serum levels of IL-6 and IL-1βwere positively correlated with CIMT.In the present study,we concluded that linagliptin could improve the levels of inflammatory factors and CIMT in newly diagnosed T2 DM patients with CAD,and IL-6 and IL-1βmight participate in the occurrence and development of CAD by influencing CIMT.本研究旨在探讨利格列汀对初诊2型糖尿病(T2DM)合并颈动脉硬化性疾病(CAD)患者的血液炎症因子水平和颈动脉内膜中层厚度(CIMT)的影响。我们将326例初诊T2DM合并CAD患者随机分为2组,对照组163例二甲双胍单药治疗,实验组163例在二甲双胍基础上联合利格列汀治疗。彩色超声多普勒测量治疗前后CIMT,ELISA法检测治疗前后IL-6和IL-1β数值,比较两组治疗前后炎症因子水平和CIMT厚度,并分析IL-6和IL-1β与CIMT的相关性。治疗24周后,结果显示实验组的炎症因子水平和CIMT均显著低于对照组(P<0.01),IL-6和IL-1β的水平与CIMT呈正相关。通过本研究得出利格列汀对初诊T2DM合并CAD患者的血液炎症因子水平和CIMT均有改善作用,IL-6、IL-1β可能通过影响CIMT参与CAD的发生和发展。

关 键 词：LINAGLIPTIN Type 2 diabetes mellitus Carotid atherosclerosis disease Inflammatory factors Carotid intima-media thickness 

分 类 号：R977[医药卫生—药品]